Jump to content

TRIM5alpha

From Wikipedia, the free encyclopedia
(Redirected from TRIM5)
TRIM5
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTRIM5, RNF88, TRIM5alpha, tripartite motif containing 5
External IDsOMIM: 608487; MGI: 4821183; HomoloGene: 75345; GeneCards: TRIM5; OMA:TRIM5 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

85363

319236

Ensembl

ENSG00000132256

ENSMUSG00000057143

UniProt

Q9C035

D3Z3L3

RefSeq (mRNA)

NM_033034
NM_033092
NM_033093

NM_001146007
NM_175677

RefSeq (protein)

NP_149023
NP_149083
NP_149084

NP_001139479
NP_783608

Location (UCSC)Chr 11: 5.66 – 5.94 MbChr 7: 103.99 – 104 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Tripartite motif-containing protein 5 also known as RING finger protein 88 is a protein that in humans is encoded by the TRIM5 gene.[5] The alpha isoform of this protein, TRIM5α, is a retrovirus restriction factor, which mediates a species-specific early block to retrovirus infection.

TRIM5α is composed of 493 amino acids which is found in the cells of most primates. TRIM5α is an intrinsic immune factor important in the innate immune defense against retroviruses, along with the APOBEC family of proteins,[6][7] tetherin and TRIM22.

Structure

[edit]

TRIM5α belongs to the TRIM protein family (TRIM stands for TRIpartite Motif); this family was first identified by Reddy in 1992 as a set of proteins which contain a RING type zinc finger domain, a B-box zinc binding domain, followed by a coiled-coil region.[8] TRIM5α bears the C-terminal PRY-SPRY or B30.2 domain in addition to the other domains.

Function and means of action

[edit]

When a retrovirus enters the host cell cytosol, the retroviral capsid was previously believed to undergo uncoating, though this (the complete uncoating theory) is now doubted; rather the true picture is thought to be that capsid uncoating does indeed take place in the cytosol but that it is a process which takes place progressively as the capsid gets closer and closer to the nucleus, though the uncoating process usually, but not always, completes in the nucleus.[9] Further, the viral genome in the capsid is reverse transcribed inside the viral capsid[10] to enable the production of daughter virions.

TRIM5α is present in the cytosol. It recognizes motifs within viral capsid proteins, which causes the TRIM5α to smother the (not yet uncoated) viral capsid in a tessilatory manner so as to form a repeating regular hexagonal net, two sides of each hexagon being made up of two spokes of a three-way hub and spoke trimer[11] and consequently by means of that smothering to interfere with any viral capsid uncoating process, thereby (1) preventing transport of the viral genome into the host cell nucleus and (2) also preventing successful reverse transcription of viral RNA into a length of DNA to be spliced into the host genome to enable expression of viral proteins via a transcrption process.[12][13] The exact mechanism of action has not been shown conclusively, but capsid protein from restricted viruses (that is viruses which are the subject of TRIM5α intervention) is removed by proteasome-dependent degradation.[14] The TRIM5α, once formed into its highly regular reticulatory net recruits ubiquitin for this purpose, which, in turn engages the proteasome.[11]

The involvement of other cellular proteins in the inhibition mediated by TRIM5α is suspected but as yet not demonstrated. However, Cyclophilin A is important for the inhibition of HIV-1 by TRIM5α in Old World monkey species.[15]

The "specificity" of restriction, that is, whether a given retrovirus can be targeted by TRIM5α, is entirely determined by the amino acid sequence of the C-terminal domain of the protein, called the B30.2/PRY-SPRY domain.[16] Amino acid 332, which occurs within this domain, seems to play a critical role in determining the specificity of retrovirus restriction.[17][18]

TRIM5α may have played a critical role in the human immune defense system about 4 million years ago, when the retrovirus PtERV1 was infecting the ancestors of modern chimpanzees.[18] While no trace of PtERV1 has yet been found in the human genome, about 130 traces of PtERV1 DNA have been found in the genome of modern chimpanzees. After recreating part of the PtERV1 retrovirus, it was reported that TRIM5α prevents the virus from entering human cells in vitro. While this cellular defense mechanism may have been very useful 4 million years ago when facing a PtERV1 epidemic, it has the side effect of leaving cells more susceptible to attack by the HIV-1 retrovirus. Recently, doubt has been cast over these conclusions. By using a PtERV1 capsid, which produces higher titer virus-like particles, Perez-Caballero et al. reported that PtERV1 is not restricted by either human or chimpanzee TRIM5α.[19]

Clinical significance

[edit]

Rhesus macaques, a species of Old World monkeys, appeared to be almost completely resistant to HIV-1, the virus that causes AIDS in humans.[20] The Rhesus macaques version of TRIM5α was very quick and had a high enough affinity to the incoming HIV capsule that it could bind and degrade it quickly so that the virus was neutralized.

Humans also have a TRIM5α, but it is not well enough tuned to mediate a sufficient response. However, the human version of TRIM5α can inhibit strains of the murine leukemia virus (MLV)[21][22] as well as equine infectious anemia virus (EIAV).[23][24]

Prior to the discovery of TRIM5α as an antiviral protein, the inhibition phenotype had been described and coined Ref1 (in human cells) and Lv1 (in monkey cells). This terminology is now largely abandoned.

A related protein, named TRIMCyp (or TRIM5-CypA), was isolated in the owl monkey, a species of New World monkey, and shown to potently inhibit infection by HIV-1.[25] A similar protein has arisen independently in Old World monkeys and has been identified in several species of macaque.[26][27]

It was recently described that interferon-α-mediated stimulation of the immunoproteasome enables human TRIM5α for effective capsid-dependent inhibition of HIV-1 DNA synthesis and infection.[28]

Notes and references

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000132256 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000057143 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG, Ballabio A (May 2001). "The tripartite motif family identifies cell compartments". EMBO J. 20 (9): 2140–51. doi:10.1093/emboj/20.9.2140. PMC 125245. PMID 11331580.
  6. ^ Cullen BR (2006). "Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors". J. Virol. 80 (3): 1067–76. doi:10.1128/JVI.80.3.1067-1076.2006. PMC 1346961. PMID 16414984.
  7. ^ Zhang KL, Mangeat B, Ortiz M, Zoete V, Trono D, Telenti A, Michielin O (2007). Aballay A (ed.). "Model structure of human APOBEC3G". PLOS ONE. 2 (4): e378. Bibcode:2007PLoSO...2..378Z. doi:10.1371/journal.pone.0000378. PMC 1849894. PMID 17440614. Open access icon
  8. ^ Reddy BA, Etkin LD, Freemont PS (1992). "A novel zinc finger coiled-coil domain in a family of nuclear proteins". Trends Biochem. Sci. 17 (9): 344–5. doi:10.1016/0968-0004(92)90308-V. PMID 1412709.
  9. ^ Matreyek KA, Yücel SS, Li X, Engelman A (2013). "Nucleoporin NUP153 Phenylalanine-Glycine Motifs Engage a Common Binding Pocket within the HIV-1 Capsid Protein to Mediate Lentiviral Infectivity". PLOS Pathogens. 9 (10): e1003693. doi:10.1371/journal.ppat.1003693. PMC 3795039. PMID 24130490.
  10. ^ Christensen DE, Ganser-Pornillos BK, Johnson JS, Pornillos O, Sundquist WI (2020). "Reconstitution and visualization of HIV-1 capsid-dependent replication and integration in vitro". Science. 370 (6513): 1–11. doi:10.1126/science.abc8420. PMC 6299210. PMID 33033190.
  11. ^ a b Fletcher AJ, Vaysburd M, Maslen S, Zeng J, Skehel JM, Towers GJ, James LC (2018). "Trivalent RING Assembly on Retroviral Capsids Activates TRIM5 Ubiquitination and Innate Immune Signaling". Cell Host Microbe. 24 (6): 761–775.e6. doi:10.1016/j.chom.2018.10.007. PMC 6299210. PMID 30503508.
  12. ^ Sebastian S, Luban J (2005). "TRIM5alpha selectively binds a restriction-sensitive retroviral capsid". Retrovirology. 2: 40. doi:10.1186/1742-4690-2-40. PMC 1166576. PMID 15967037.
  13. ^ Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J (2006). "Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor". Proc. Natl. Acad. Sci. U.S.A. 103 (14): 5514–9. doi:10.1073/pnas.0509996103. PMC 1459386. PMID 16540544.
  14. ^ Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ (2006). "Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection". Proc. Natl. Acad. Sci. U.S.A. 103 (19): 7465–70. Bibcode:2006PNAS..103.7465W. doi:10.1073/pnas.0510483103. PMC 1464362. PMID 16648264.
  15. ^ Berthoux L, Sebastian S, Sokolskaja E, Luban J (2005). "Cyclophilin A is required for TRIM5α-mediated resistance to HIV-1 in Old World monkey cells". Proc. Natl. Acad. Sci. U.S.A. 102 (41): 14849–53. Bibcode:2005PNAS..10214849B. doi:10.1073/pnas.0505659102. PMC 1239943. PMID 16203999.
  16. ^ Ohkura S, Yap MW, Sheldon T, Stoye JP (2006). "All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction". J. Virol. 80 (17): 8554–65. doi:10.1128/JVI.00688-06. PMC 1563890. PMID 16912305.
  17. ^ Yap MW, Nisole S, Stoye JP (2005). "A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction". Curr. Biol. 15 (1): 73–8. Bibcode:2005CBio...15...73Y. doi:10.1016/j.cub.2004.12.042. PMID 15649369. S2CID 1910582.
  18. ^ a b Kaiser SM, Malik HS, Emerman M (2007). "Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein". Science. 316 (5832): 1756–8. Bibcode:2007Sci...316.1756K. doi:10.1126/science.1140579. PMID 17588933. S2CID 33225147.
  19. ^ Perez-Caballero D, Soll SJ, Bieniasz PD (2008). Hope TJ (ed.). "Evidence for restriction of ancient primate gammaretroviruses by APOBEC3 but not TRIM5alpha proteins". PLOS Pathog. 4 (10): e1000181. doi:10.1371/journal.ppat.1000181. PMC 2564838. PMID 18927623. Open access icon
  20. ^ Tenthorey, Jeannette L; Young, Candice; Sodeinde, Afeez; Emerman, Michael; Malik, Harmit S (2020-09-15). Schoggins, John W; Weigel, Detlef; Berthoux, Lionel (eds.). "Mutational resilience of antiviral restriction favors primate TRIM5α in host-virus evolutionary arms races". eLife. 9: e59988. doi:10.7554/eLife.59988. ISSN 2050-084X. PMC 7492085. PMID 32930662.
  21. ^ Lee K, KewalRamani VN (2004). "In defense of the cell: TRIM5α interception of mammalian retroviruses". Proc. Natl. Acad. Sci. U.S.A. 101 (29): 10496–7. doi:10.1073/pnas.0404066101. PMC 489964. PMID 15252204.
  22. ^ Yap MW, Nisole S, Lynch C, Stoye JP (2004). "Trim5α protein restricts both HIV-1 and murine leukemia virus". Proc. Natl. Acad. Sci. U.S.A. 101 (29): 10786–91. Bibcode:2004PNAS..10110786Y. doi:10.1073/pnas.0402876101. PMC 490012. PMID 15249690.
  23. ^ Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD (2004). "Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5α". Proc. Natl. Acad. Sci. U.S.A. 101 (29): 10774–9. Bibcode:2004PNAS..10110774H. doi:10.1073/pnas.0402361101. PMC 490010. PMID 15249685.
  24. ^ Keckesova Z; Ylinen LM; Towers GJ (2004). "The human and African green monkey TRIM5αgenes encode Ref1 and Lv1 retroviral restriction factor activities". Proc. Natl. Acad. Sci. U.S.A. 101 (29): 10780–5. Bibcode:2004PNAS..10110780K. doi:10.1073/pnas.0402474101. PMC 490011. PMID 15249687.
  25. ^ Sayah DM, Sokolskaja E, Berthoux L, Luban J (2004). "Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1". Nature. 430 (6999): 569–73. Bibcode:2004Natur.430..569S. doi:10.1038/nature02777. PMID 15243629. S2CID 4379907.
  26. ^ Wilson SJ, Webb BL, Ylinen LM, Verschoor E, Heeney JL, Towers GJ (2008). "Independent evolution of an antiviral TRIMCyp in rhesus macaques". PNAS. 105 (9): 3557–62. Bibcode:2008PNAS..105.3557W. doi:10.1073/pnas.0709003105. PMC 2265179. PMID 18287035.
  27. ^ Brennan G, Kozyrev Y, Hu SL (2008). "TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis". PNAS. 105 (9): 3569–74. Bibcode:2008PNAS..105.3569B. doi:10.1073/pnas.0709511105. PMC 2265124. PMID 18287033.
  28. ^ Malim, Michael H.; Gilberto Betancor; Apolonia, Luis; Jimenez-Guardeño, Jose M. (2019-03-18). "Immunoproteasome activation enables human TRIM5α restriction of HIV-1". Nature Microbiology. 4 (6): 933–940. doi:10.1038/s41564-019-0402-0. ISSN 2058-5276. PMC 6544544. PMID 30886358.
[edit]

See also

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=TRIM5alpha&oldid=1249074646"